Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Cargando...

Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm. 2015 Dec;37(6):1021-7. doi: 10.1007/s11096-015-0195-z. Epub 2015 Sep 21. PubMed PMID: 26391788.

AÑO: 2015; IF: 2.305

26391788

Gabaldó Barrios X, Sarabia Meseguer MD, Alonso Romero JL, Marín Vera M, Marín Zafra G, Sánchez Henarejos P, Sánchez Bermúdez AI, Ruiz Espejo F. Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry. Fam Cancer. 2014 Sep;13(3):431-5. doi: 10.1007/s10689-014-9708-5. PubMed PMID: 24633894.

AÑO: 2014; IF: 2.209

24633894

Sacramento Díaz-Carrasco M, Ramírez C, Montenegro S, Alonso-Romero JL. [An unexpected and severe infusion reaction induced by trastuzumab]. Farm Hosp. 2014 May 1;38(3):254-5. doi: 10.7399/fh.2014.38.3.1169. Spanish. PubMed PMID: 24951913.

AÑO: 2014

24951913

Esquerdo G, Doménech M, López P, Pedro C, Villadiego K, Constenla M, Sánchez-Rovira P, Gasquet JA, Rodríguez CA; AVANT study group. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy. Tumori. 2014 Mar-Apr;100(2):225-31. doi: 10.1700/1491.16423. PubMed PMID: 24852870.

AÑO: 2014; IF: 1.234

24852870

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804. Erratum in: Lancet. 2017 May 13;389(10082):1884. PubMed PMID: 23219286; PubMed Central PMCID: PMC3596060.

AÑO: 2013; IF: 59.102

23219286

< Anterior Siguiente >

Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Instituto de Investigación Sanitaria Acreditado

ONCOLOGÍA CLÍNICA Y TRASLACIONAL